Chinook Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Chinook Therapeutics (NASDAQ: KDNY) will participate in two upcoming virtual investor conferences. The first is the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 10:15 am EDT, featuring a fireside chat. The second event is the Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, at 3:30 pm EDT, where Chinook will present.

Archived recordings of both presentations will be available on Chinook’s website for 90 days. The company focuses on developing precision medicines for kidney diseases, including programs targeting IgA nephropathy and primary hyperoxaluria.

SEATTLE, April 08, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in the following upcoming virtual investor conferences:

• 20^th Annual Needham Virtual Healthcare Conference – fireside chat on Wednesday, April 14^th at 10:15 am EDT
  
  
• Bloom Burton & Co. Healthcare Investor Conference – presentation on Tuesday, April 20^th at 3:30 pm EDT
  

To access the live webcasts and subsequent archived recordings of these and other company presentations, please visit the Investors section of Chinook’s website. The archived webcasts will remain available for replay on Chinook’s website for 90 days.

About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.

Contact:
Noopur Liffick
Vice President, Investor Relations & Corporate Communications
investors@chinooktx.com
media@chinooktx.com

FAQ

What are the dates for Chinook Therapeutics' virtual investor conferences in April 2021?

Chinook Therapeutics will participate in the Needham Virtual Healthcare Conference on April 14, 2021, and the Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021.

What time is Chinook's presentation at the Needham Virtual Healthcare Conference?

Chinook's fireside chat at the Needham Virtual Healthcare Conference is scheduled for April 14, 2021, at 10:15 am EDT.

Where can I find archived recordings of Chinook Therapeutics' presentations?

Archived recordings of Chinook Therapeutics' presentations will be available on their website for 90 days after the events.

What is the focus of Chinook Therapeutics' pipeline?

Chinook Therapeutics focuses on developing precision medicines for kidney diseases, particularly IgA nephropathy and other severe chronic kidney disorders.

What is Chinook's lead program for kidney diseases?

Chinook's lead program is atrasentan, an endothelin receptor antagonist in phase 3 development for IgA nephropathy.